HOOKIPA Pharma Inc. Reports Q1 Net Loss of $18M
HOOKIPA Pharma Inc. (HOOK) today reported financial results and business highlights for the first quarter of 2022.“We observed strong external validation of our novel arenaviral platform in...
Buy
or
Gilead News & Analysis
-
-
Friday Upgrades Downgrades: AppLovin, BioCryst Pharma, Boeing, CF Industries, Coupa Software, Dutch Bros, DigitalOcean, Gilead Sciences, IBM, Rivian, Roblox, VICI Properties, Visa, Walt Disney
Friday's top analyst upgrades and downgrades included AppLovin, BioCryst Pharmaceuticals, Boeing, CF Industries, Coupa Software, Crocs, Dutch Bros, DigitalOcean, Gilead Sciences, IBM,...
-
Monday’s Top Analyst Upgrades and Downgrades: Amazon.com, Apple, Caterpillar, Comcast, Comerica, Gilead Sciences, Intel, Lululemon Athletica, McDonald’s and More
Monday's top analyst upgrades and downgrades included Amazon.com, Apple, Caterpillar, Comcast, Comerica, Gilead Sciences, Intel, Lululemon Athletica and McDonald's.
-
Why These Analysts Are Bullish On Gilead's Q1 Earnings
RBC Capital Market views Gilead Sciences Inc's (NASDAQ: GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite...
-
Gilead Sciences Reports Q1 Earnings Beat, Provides Guidance
Gilead Sciences (NASDAQ:GILD) reported its Q1 results, with EPS of $2.12 coming in better than the consensus estimate of $1.81. Revenue grew 3% year-over-year to $6.6 billion, compared to...
-
Gilead Sciences Tops Q1 EPS by 31c
Gilead Sciences (NASDAQ:GILD) reported Q1 EPS of $2.12, $0.31 better than the analyst estimate of $1.81. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of...
-
Gilead Earnings, Revenue beat In Q1
Investing.com - Gilead (NASDAQ:GILD) reported on Thursday first quarter {{erl-6365||earnings that beat analysts' forecasts and revenue that topped expectations. Gilead announced earnings...
-
How Gilead is positioning Veklury vs. such COVID antivirals as Paxlovid
How Gilead is positioning Veklury vs. such COVID antivirals as Paxlovid
-
: How Gilead is positioning its COVID-19 drug against newer antivirals like Paxlovid
The company has an oral version of its COVID-19 drug Veklury in a clinical trial.
-
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Protagonist's Ulcerative Colitis Study Disappoints With Higher Dose Of PN-943 Protagonist...
-
Gilead's Remdesivir Becomes First Approved Treatment For Pediatric COVID-19 Patients
The FDA has approved Gilead Sciences Inc's (NASDAQ: GILD) supplemental marketing application for Veklury (remdesivir) for pediatric COVID-19 patients older than 28 days. The approval covers...
-
FDA formally approves Gilead's Veklury for young children
The Food and Drug Administration said Monday it expanded the approval of Gilead Sciences Inc.'s Veklury to include pediatric patients between the ages of four weeks and 12 years old....
-
Monday’s Top Upgrades and Downgrades: Advanced Micro Devices, DoorDash, Freeport-McMoRan, Gap, Gilead Sciences, KeyCorp, Marvell Technology, McDonald’s, PayPal, Snap, Snowflake, United Airlines
Monay's top analyst upgrades and downgrades included Advanced Micro Devices, Danaher, DoorDash, Freeport-McMoRan, Gap, Gilead Sciences, Huntington Bancshares, Independence Realty Trust,...
-
Can Gilead Stock Gain Traction Following FDA Lifting Partial Hold?
The U.S. Food and Drug Administration has lifted the partial clinical hold order on Gilead Sciences, Inc.'s (GILD) blood cancer drug combination trials. The hold was initially placed on five...
-
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Aeglea Shares Additional Phase 3 Data In Inherited Metabolic Disease Aeglea BioTherapeutics...
-
RBC: the FDA lifting the hold on Gilead's experimental cancer therapy is a 'much-need piece of good news'
The Food and Drug Administration's decision on Monday to lift the partial hold on Gilead Sciences Inc.'s magrolimab for two indications is "good news" for the company, according to RBC...
-
FDA Lifts Partial Clinical Hold On Gilead's MDS, AML Magrolimab Studies
The FDA has lifted the partial clinical hold on Gilead Sciences Inc's (NASDAQ: GILD) studies evaluating magrolimab combined with azacitidine. The FDA removed the partial clinical hold...
-
FDA Removes Partial Clinical Hold on Gilead's MDS and AML Magrolimab Studies
Gilead Sciences, Inc. (Nasdaq: NASDAQ:GILD) announced that the U.S. Food and Drug Administration (FDA) decided to remove its partial clinical hold on the company's studies investigating...
-
Dow Jones Newswires: Gilead says FDA lifts partial clinical hold on MDS and AML magrolimab studies
The U.S. Food and Drug Administration has lifted a partial clinical hold on studies evaluating magrolimab in combination with azacitidine, Gilead Sciences Inc. said Monday.
-
Agenus' CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead
LEXINGTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response...
-
Gilead's Yescarta Scores FDA Approval As First CAR T-Cell Therapy For Earlier Lymphoma
The FDA approved the expanded use of Gilead Sciences Inc's (NASDAQ: GILD) Yescarta, a cell therapy made by the Kite Pharma unit. The approval covers Yescarta (axicabtagene ciloleucel) for...
-
Gilead’s Yescarta Immunotherapy Wins FDA Approval
Kite, a unit of biopharmaceutical company Gilead Sciences (NASDAQ: GILD), announced that the U.S. Food and Drug Administration (FDA) has approved its Yescarta CAR T-cell immunotherapy. The...
-
Gilead Earnings miss, Revenue beats In Q4
Investing.com - Gilead (NASDAQ:GILD) reported on Tuesday fourth quarter {{erl-6365||earnings that missed analysts' forecasts and revenue that topped expectations. Gilead announced earnings...
-
Galapagos Surges On New CEO and Upgrade News
By Sam Boughedda Investing.com — Shares of Belgian pharmaceutical research company Galapagos NV ADR (NASDAQ:GLPG) are up more than 21% a day after the company appointed its new CEO. Citi...
-
Gilead Falls as Sales of Non-Covid Drugs Seen Weaker
By Dhirendra Tripathi Investing.com – Gilead Sciences stock (NASDAQ:GILD) fell more than 4% Friday as the maker of remdesivir said sales of non-Covid drugs would be lower in 2021 than...
-
Gilead Earnings, Revenue beat In Q3
Investing.com - Gilead (NASDAQ:GILD) reported on Thursday third quarter {{erl-6365||earnings that beat analysts' forecasts and revenue that topped expectations. Gilead announced earnings...
-
Gilead Earnings, Revenue beat In Q2
Investing.com - Gilead (NASDAQ:GILD) reported on Thursday second quarter {{erl-6365||earnings that beat analysts' forecasts and revenue that topped expectations. Gilead announced earnings...
-
Zoom, Facebook and Delta Air Lines Fall Premarket
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, July 19th. Please refresh for updates. Zoom Video Communications (NASDAQ:ZM) stock fell 2.2% after the...
-
South Africa's vaccine quagmire, and what needs to be done now
Photo by Sharon Seretlo/Gallo Images via Getty ImagesSouth Africa’s approach to its COVID-19 vaccine programme has been characterised by a large number of...
-
US STOCKS-Wall Street set to take a breather; on track for weekly gains
* Twitter (NYSE:TWTR) plunges on grim outlook* Chevron down as profit drops on weaker refining margins* U.S. consumer spending rebounds in March* Futures down: Dow 0.49%, S&P 0.62%, Nasdaq...
-
US STOCKS-Futures retreat; main indexes on track for weekly gains
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)* Futures down: Dow 0.53%, S&P 0.65%, Nasdaq 0.83%By Shivani KumaresanApril 30...
-
Gilead Earnings beat, Revenue misses In Q1
Investing.com - Gilead (NASDAQ:GILD) reported on Thursday first quarter {{erl-6365||earnings that beat analysts' forecasts and revenue that fell short of expectations. Gilead announced...
-
US STOCKS-Facebook fuels S&P 500 to record high close
* Apple nearly unchanged after strong quarterly results* Communication services leads gains among S&P 500 sectors* U.S. economy accelerates in Q1; jobless claims edge lower (Updates with...
-
US STOCKS-Facebook lifts S&P 500 to record high
* Apple higher after strong quarterly results* Communication services leads gains among S&P 500 sectors* U.S. economy accelerates in Q1; jobless claims edge lower* Indexes: Dow +0.53%, S&P...
-
US STOCKS-S&P 500 near record high on Facebook boost, Nasdaq eases
* Apple slips despite strong quarterly results* Communication services leads gains among S&P 500 sectors* U.S. economy accelerates in Q1; jobless claims edge lower* Indexes: Dow up 0.12%,...
-
US STOCKS-S&P 500, Nasdaq hit record highs on tech earnings boost, upbeat data
* Apple, Facebook jump on strong earnings* Communication services leads gains among S&P 500 sectors* U.S. economy accelerates in Q1; jobless claims edge lower* Indexes up: Dow 0.39%, S&P...
-
US STOCKS-Apple, Facebook set to boost Wall Street after strong earnings
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)* Apple, Facebook jump on strong earnings* U.S. economy accelerates in Q1;...
-
US STOCKS-Apple, Facebook drive Nasdaq futures higher as earnings roll in
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)* Futures up: Dow 0.52%, S&P 0.72%, Nasdaq 1.00%By Shivani KumaresanApril 29...
-
Economic Calendar - Top 5 Things to Watch This Week
By Jesse Cohen Investing.com - Market participants are bracing for heightened volatility as the coming week will be dominated by several market-moving events, including a deluge of...
-
Gilead Earnings, Revenue beat In Q4
Investing.com - Gilead (NASDAQ:GILD) reported on Thursday fourth quarter {{erl-6365||earnings that beat analysts' forecasts and revenue that topped expectations. Gilead announced earnings...
-
Top 5 Things to Watch in Markets in the Week Ahead
By Noreen Burke Investing.com -- A big week for earnings, including reports from Amazon and Alphabet, stimulus negotiations in Washington and the first jobs report of 2021 will all be major...
-
UPDATE 2-Upbeat business activity, vaccine hopes lift European shares
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* Euro zone PMIs top estimates* Continental jumps, sharply hikes EBIT forecast* EU...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
